That is, do I understand correctly that Frequency Therapeutics conducted the testing themselves, and summed up the results and results themselves? Do you trust this company? Why can we trust that their goals are honest? What is your position on this issue? It is very likely that their goal is to make money not so much by creating a medicine as by deceiving the trust of investors.
The early published work was conducted by the founders prior to forming the company, under a lab operated by the highly-respected Robert Langer (also, the founder of Moderna, and others). Langer is also a co-founder.
Published work is peer-reviewed by entities that do not have a conflict of interest, and must meet certain scientific / academic standards. So, it's not the company making stuff up for its own gain / interests.
Frequency Therapeutics is publicly-traded. It is regulated by the US Securities and Exchange Commission (SEC). As an SEC Regulated firm, it is required to be fairly transparent with stockholders and the public in regards to its financial health, operations, and communication, among other things. Communications include investor presentations, marketing, etc, are fairly well regulated and the rules concerning them are clearly defined by the SEC.
Frequency Therapeutics as a drug developer, is also regulated by the FDA when it conducts clinical trials on its treatments. The FDA requires that drugs in clinical trials are tested by independent, FDA sponsored testing sites, and are placebo controlled. The FDA has essentially 100% say on what the firm can and cannot do with regards to patient inclusion/exclusion on the trials, number of test sites, etc. So, the firm doesn't have much ability to influence the outcomes of their trials in their favor.
Diesel's Personal Thoughts on Trusting the Science and the Firm:
- Progenitor Cell Activation (PCA) looks to be promising from an academic standpoint, FX-322 seems to have an effect on specific patients. It's likely to see a commercial outcome.
- The firm is highly regulated by two federal bodies: The SEC and FDA. They're not big enough or have deep enough pockets to pull a "fast one" on investors without severe penalties from either. So, they're incentives to be honest.
- Bob Langer, the PCA advisory board, the board, and most of the leadership at the company have a LONG career history in therapeutic development, hearing, and academic research/science. I find it hard to believe that all would want to tarnish their careers by running a scam. Also, many of the on-camera interviews seem to have genuine, honest interactions about the future of PCA/hearing regen and the learnings from failures.
- FX-345 and FX-322 existing in the trial pipeline concurrently is a signal of the firm's commitment to continue to improve its hearing treatment product. In my opinion, it adds legitimacy to the science. Drug development is highly expensive, and these types of small firms operate at high risk with one drug alone. One mistake can bankrupt. Having two in the pipeline shows they are committing to continuing the first-gen product (FX-322), while developing a second-gen product (FX-345). A company seeking to mislead investors wouldn't continue to sink money into the first-gen, they'd just switch to the "newest thing" and move on.
I have spoken.